Kininogen-1 is a secreted protein which contains three cystatin domains. There are two alternatively spliced forms, designated as the high molecular weight (HMW) and low MW (LMW) forms. Kininogen-1 plays a critical role in blood coagulation and inflammatory response. Kininogens are inhibitors of thiol proteases. Kininogen-1 participates in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII, also inhibits the thrombin- and plasmin-induced aggregation of thrombocytes. The active peptide bradykinin that is released from Kininogen-1 shows a variety of physiological effects: influence in smooth muscle contraction, induction of hypotension, natriuresis and diuresis, decrease in blood glucose level. It is a mediator of inflammation and causes increase in vascular permeability, stimulation of nociceptors release of other mediators of inflammation. It has a cardioprotective effect. LMW-kininogen inhibits the aggregation of thrombocytes and doesn't involved in blood clotting.
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 μg | ¥ 1,170 | 5日内发货 | |
| 50 μg | ¥ 3,470 | 5日内发货 | |
| 500 μg | ¥ 12,100 | 5日内发货 | |
| 1 mg | ¥ 17,400 | 5日内发货 |
| 生物活性 | Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first. |
| 产品描述 | Kininogen-1 is a secreted protein which contains three cystatin domains. There are two alternatively spliced forms, designated as the high molecular weight (HMW) and low MW (LMW) forms. Kininogen-1 plays a critical role in blood coagulation and inflammatory response. Kininogens are inhibitors of thiol proteases. Kininogen-1 participates in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII, also inhibits the thrombin- and plasmin-induced aggregation of thrombocytes. The active peptide bradykinin that is released from Kininogen-1 shows a variety of physiological effects: influence in smooth muscle contraction, induction of hypotension, natriuresis and diuresis, decrease in blood glucose level. It is a mediator of inflammation and causes increase in vascular permeability, stimulation of nociceptors release of other mediators of inflammation. It has a cardioprotective effect. LMW-kininogen inhibits the aggregation of thrombocytes and doesn't involved in blood clotting. |
| 种属 | Human |
| 表达系统 | HEK293 Cells |
| 标签 | C-6xHis |
| 蛋白编号 | P01042-2 |
| 别名 | Williams-Fitzgerald-Flaujeac Factor,lpha-2-Thiol Proteinase Inhibitor,KNG1,KNG,Kininogen-1,HMWK,High Molecular Weight Kininogen,Fitzgerald Factor,BDK |
| 氨基酸序列 | Gln19-Ser427 |
| 蛋白构建 | Gln19-Ser427 |
| 蛋白纯度 | Greater than 95% as determined by reducing SDS-PAGE. (QC verified) |
| 分子量 | 61 KDa (reducing condition) |
| 内毒素 | < 0.1 ng/µg (1 EU/µg) as determined by LAL test. |
| 缓冲液 | Lyophilized from a solution filtered through a 0.22 μm filter, containing 20 mM Hac-NaAC, 150 mM NaCl, pH 4.0. |
| 复溶方法 | Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
| 存储 | Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
| 运输方式 | In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
| 研究背景 | Kininogen-1 is a secreted protein which contains three cystatin domains. There are two alternatively spliced forms, designated as the high molecular weight (HMW) and low MW (LMW) forms. Kininogen-1 plays a critical role in blood coagulation and inflammatory response. Kininogens are inhibitors of thiol proteases. Kininogen-1 participates in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII, also inhibits the thrombin- and plasmin-induced aggregation of thrombocytes. The active peptide bradykinin that is released from Kininogen-1 shows a variety of physiological effects: influence in smooth muscle contraction, induction of hypotension, natriuresis and diuresis, decrease in blood glucose level. It is a mediator of inflammation and causes increase in vascular permeability, stimulation of nociceptors release of other mediators of inflammation. It has a cardioprotective effect. LMW-kininogen inhibits the aggregation of thrombocytes and doesn’t involved in blood clotting. |
嗨！有任何问题？点我咨询
